Pfizer (PFE) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of ...

Pfizer is expected to announce its second-quarter results next month, and analysts predict a single-digit drop in the company ...

Irvine, California-based Edwards Lifesciences Corporation (EW) provides products and technologies to treat advanced ...

GSK's Q1 2025 earnings will reveal progress in specialty medicines amid regulatory headwinds. Learn what to watch when the pharmaceutical giant reports results on 30 April.

Pfizer Inc.'s stock has performed poorly despite massive COVID-19 earnings, trading at a 12-year low due to flawed M&A deals and high debt levels. The discontinuation of danuglipron, a potential ...

Pfizer’s PFE 2024 revenue reached $63.6 billion, near the high end of its $61 billion-$64 billion guidance range. Management reaffirmed expectations for 2025 revenue of $61 billion-$64 billion ...

Vedanta Ltd, Sun Pharmaceutical Industries Ltd, and Pfizer Ltd are among 135 companies set to release their third-quarter (Q3) earnings reports for the financial year 2024-25 (FY25) on January 31, ...

Financial analysis of Pfizer Inc. stock ahead of its earnings release. PFE faces significant headwinds from patent expiries, click for my updated look at the stock.

Our interactive dashboard analysis of Pfizer’s FY 2024Q3 Earnings Preview has more details on the company’s revenues and earnings for the quarter.

Pfizer (PFE) will report Q3 2024 earnings on October 29, with expectations of $15.19 billion in sales and earnings of $0.64 per share. Pfizer has consistently beaten earnings estimates, with a ...

Anyway, that’s the take on Merck and Pfizer post-earnings. Pfizer is the safer of the two stocks, but Merck has better upside potential if the weakness isn’t repeated in Q3 ’24.

Wall Street expects a year-over-year decline in earnings on higher revenues when Pfizer (PFE) reports results for the quarter ended June 2024. While this widely-known consensus outlook is ...